Hospital
ST Luke's Jones Regional Medical Center
ST Luke's Jones Regional Medical Center was paid $1.54M by Medicaid between Jan 2018 and Dec 2024, across 49 billing codes. Its largest line is 0241U, Neonatal screening for hereditary disorders, genomic sequence analysis panel — 12% of everything it billed.
33Billing provider infoST LUKE'S JONES REGIONAL MEDICAL CENTER
ANAMOSA, IA 52205
ANAMOSA, IA 52205
33aNPI1164514741assigned 09/29/2006
33bProvider typeCritical Access Hospital
28Total paid$1.54M
24GClaims39,581
24DCodes billed49
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Iowa
Rank by total paid#24 of 79
Median peer was paid$801K
This provider vs. median1.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,421 | $281K | |
| 2019 | 7,791 | $223K | |
| 2020 | 4,432 | $161K | |
| 2021 | 6,238 | $328K | |
| 2022 | 5,656 | $255K | |
| 2023 | 4,823 | $143K | |
| 2024incomplete | 3,220 | $153K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 12% | 1,005 | 986 | $183K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 845 | 670 | $167K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.9% | 1,255 | 1,130 | $153K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 9.4% | 1,704 | 1,680 | $144K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 7.6% | 9,173 | 8,708 | $118K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 6.6% | 509 | 502 | $102K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 6.0% | 5,744 | 5,466 | $93K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.3% | 1,324 | 1,224 | $82K |
| 0240U | 3.4% | 363 | 358 | $52K | |
| 80053 | Comprehensive metabolic panel | 3.3% | 1,243 | 1,131 | $51K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.9% | 1,696 | 1,548 | $44K |
| 87428 | 2.4% | 412 | 387 | $37K |
37 more codes
| 36415 | Collection of venous blood by venipuncture | 2.3% | 4,721 | $36K |
| 71046 | Radiologic examination, chest; 2 views | 1.7% | 204 | $26K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.7% | 1,119 | $26K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.5% | 908 | $24K |
| 83605 | 1.2% | 638 | $19K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 1.2% | 624 | $18K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 347 | $18K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.1% | 237 | $17K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.1% | 852 | $17K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 488 | $15K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 341 | $15K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 358 | $12K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 155 | $11K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 165 | $10K |
| 87486 | <1% | 494 | $9K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 63 | $8K |
| 87581 | <1% | 561 | $7K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 361 | $6K |
| 84484 | <1% | 129 | $5K | |
| 86738 | <1% | 115 | $3K | |
| 87631 | <1% | 35 | $3K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 121 | $3K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 206 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 99 | $2K |
| 83690 | <1% | 51 | $1K | |
| 85018 | <1% | 379 | $1K | |
| 82550 | <1% | 56 | $1K | |
| 81002 | <1% | 296 | $972.96 | |
| 71045 | Radiologic examination, chest; single view | <1% | 17 | $936.65 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 37 | $932.94 |
| 80061 | Lipid panel | <1% | 39 | $833.32 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 12 | $379.10 |
| 81001 | <1% | 18 | $201.11 | |
| 87807 | <1% | 14 | $172.60 | |
| 81003 | <1% | 14 | $153.27 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 15 | $15.99 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 19 | $1.02 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBRIESEMEISTER, ERIC (CEO)
| Provider | Location | Paid |
|---|---|---|
| ST Luke's Jones Regional Medical Center | Anamosa, IA | $2.81M |
| ST Luke's Jones Regional Medical Center | Anamosa, IA | $2.06M |
| ST Luke's Jones Regional Medical Center | Vinton, IA | $1.49M |
| ST Luke's Jones Regional Medical Center | Monticello, IA | $1.38M |
| ST Luke's Jones Regional Medical Center | Belle Plaine, IA | $1.27M |
| ST Luke's Jones Regional Medical Center | Clarence, IA | $1.00M |
| ST Luke's Jones Regional Medical Center | Tipton, IA | $908K |
| ST Luke's Jones Regional Medical Center | Shellsburg, IA | $349K |
| ST. Luke's Jones Regional Medical Center | Anamosa, IA | $193K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.